• Nidhal K. Maraie Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
  • Yasser Q. Almajidi Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
  • Ahmed Alshadher The National Center for Drugs Control and Research, Baghdad, Iraq




Bioavailability study, In situ gel, Nanoemulsion, NIG, Ondansetron HCl


Objective: The aim of the work was to study the absolute and relative bioavailability (using rabbits) of ondansetron HCl (ONH)from our newly prepared intranasal mucoadhesive nanoemulsion in situ gel (NIG) in comparison to intranasal mucoadhesive in situ gel (IG) prepared by the conventional method and intravenous injection.

Methods: Six male rabbits weighing 2.5-3 kg were used in this study, where the dose of ondansetron HCl (ONH) was calculated based on the body surface area (BSA) which is equivalent to 140μl (containing 10 mg/ml) of NIG and IG and 700μl of intravenous Zofran® injection (containing 2 mg/ml) were given to the rabbits, separated with one week washout period. Serial blood samples were withdrawn and analyzed for simultaneous determination of the drug using HPLC (Knaure; 150 ×4.6 mm; 5 μm particle size; 25 cm length) supported by guard column C18-4 mm diameter.

Results: The pharmacokinetics parameters for NIG; Cmax, Tmax, AUC0-t, AUC0-∞were found to be greater than conventional in situ gel (IG). In vivo pharmacokinetic studies in rabbits showed a significant increase in Cmax and AUC 0-α(P<0.001) with shorter Tmaxusing NIG compared to IG containing the same NIG excipients, while the absolute bioavailability for NIG and IG (was 80.541 and 51.068 respectively).

Conclusion: The present studies ratify the bioavailability enhancement potential of NE used to prepare NIG for the drug and significantly high absolute bioavailability to be used as a successful alternative route to the IV injection and improve patient compliance.


Download data is not yet available.


USP DI. The United States Pharmacopoeial convention Inc. 15th edn. Rockville, MD; 1995. p. 2062-3.

Menaka M, Pandey VP, Smith AA. Colloidal dispersions as a potential nasal drug delivery system forondansetron hydrochloride–in vitro and in vivo properties. Asian J Pharm Clin Res 2014;7:72-5.

Srivastava R, Srivastava S, Singh SP. Thermoreversible in-situ nasal gel formulations and their pharmaceutical evaluation for the treatment of allergic rhinitis containing extracts of Moringa olifera and Embelia ribes. Int J Appl Pharm 2017;9:16-20.

Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3-21.

Romeo VD, deMeireles J, Sileno AP. Effects of physicochemical properties and other factors on systemic, nasal drug delivery. Adv Delivery Rev 1998;29:89-116.

Shafiq A. Design and development of oral oil in water ramipril nanoemulsion formulation. In vitro and in vivo assessment. J Biomed Nanotech 2007;3:280-44.

Ugwoke MI, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, application, trends and future perspectives. Adv Drug Delivery Rev 2005;57:1640-65.

Maraie NK, Almajidi YQ. Effect of different mucoadhesive polymers on the release of ondansetron HCl from intranasal mucoadhesive in situ gel. Afr J Plant Sci 2017;17:76-85.

Maraie NK, Almajidi YQ. Application of nanoemulsion technology for preparation and evaluation of intranasal mucoadhesive nano-in situ gel for ondansetron HCl. J Global Pharma Technol 2018;10:431-42.

Shaw SR, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEBj 2007;22:659-61.

Glaxo Smith Kline. Zofran (ondansetron hydrochloride) injection prescribing information. Research Triangle Park. NC; 2012.

Ponnuri RNL, Pragallapati P, Ravindra N, Mandava VBR. A rapid and sensitive liquid chromatography-mass spectrometry/mass spectrometry method for estimation of pioglitazone, keto pioglitazone and hydroxy pioglitazone in human plasma. Asian J Pharm Clin Res 2017;10:120-8.

Owayez AS, Abd El-ghany GM, Abu Hashim. Pharmaceutical studies on formulation and evaluation of sustained release tablets containing certain drugs. M. Sc. thesis, Mansoura University; 2017. p. 107.

Moreira RF. Development and validation of a rapid and sensitive LC-ESI-MS/MS method for ondansetron quantification in human plasma and its application in comparative bioavailability study. Biomed Chromatogr 2010;24:1220–7.

Tewthanom K, Jongjaroenprasert W. The pharmacokinetics of 2 doses (50 mg and 100 mg) levothyroxine treatment in athyreotic patients. Int J Appl Pharm 2016;8:66-8.

Bauer LA. Applied clinical pharmacokinetic. Seconded. USA: McGraw-hills; 2008. p. 21-3.

Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Fourth ed. Lea and Febiger: Malvem, PA; 1991. p. 23-8.

Shargel L, pong SW, yu ABC. Applied biopharmaceutical and pharmacokinetics. Fifth ed. USA: McGraw-hills; 2004. p. 56-8.

Devkar TB, Tekade AR, Khandelwal KR. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using delonix regia gum as a natural mucoadhesive polymer. Colloids Surf B 2014:122:143-50.

Vandenberg CM, Kazmi Y, Stewart J, Weidler DJ, Tenjarla SN, Earl S. et al. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-Mg oral tablet, rectal suppository, and IV. Infusion. Am J Hosp Pharm 2000;57:45-8.



How to Cite

Maraie, N. K., Almajidi, Y. Q., & Alshadher, A. (2018). ABSOLUTE AND RELATIVE BIOAVAILABILITY STUDY FOR THE NEWLY DEVELOPED NASAL NANOEMULSION IN SITU GEL OF ONDANSETRON HCl IN COMPARISON TO CONVENTIONALLY PREPARED IN SITU GEL AND INTRAVENOUS DOSAGES FORMS. International Journal of Applied Pharmaceutics, 10(5), 105–109. https://doi.org/10.22159/ijap.2018v10i5.27396



Original Article(s)